Novavax Inc. ($NVAX) Stock Forecast: Down 6.0% Today

What is Novavax Inc.?

Novavax (NVAX) is a biotechnology company focused on developing vaccines for infectious diseases. The stock market had a bearish movement today.

Why is Novavax Inc. going down?

NVAX stock is down 6.0% on Apr 1, 2025 16:26

• NVAX stock dipped more than the broader market, closing at $7.26, marking a -1.76% move from the prior day.
• Biotech stocks, including Novavax, fell after a top FDA official resigned due to irreconcilable differences with the new HHS Secretary, causing uncertainty in the sector.
• Reports about the Trump administration planning to cease financial support for vaccine alliance Gavi and scale back efforts to combat malaria added to the negative sentiment surrounding biotech stocks like Novavax.
• The combination of internal FDA issues and external government funding concerns likely contributed to the bearish movement in NVAX stock today.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.

The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.

https://www.zacks.com/stock/news/2437914/biotech-stocks-fall-after-top-fda-official-quits-over-clash-with-rfk-jr

Why Novavax ( NVAX ) Dipped More Than Broader Market Today

Novavax (NVAX) closed at $7.26 in the latest trading session, marking a -1.76% move from the prior day.

https://www.zacks.com/stock/news/2436464/why-novavax-nvax-dipped-more-than-broader-market-today

Moderna, Novavax Shares Are Sliding Wednesday: What's Going On? - Moderna ( NASDAQ:MRNA )

The Trump administration reportedly plans to cease financial support for vaccine alliance Gavi. The Trump administration is also planning to "significantly scale back" support for efforts to combat malaria. Feel unsure about the market's next move?

https://www.benzinga.com/news/global/25/03/44498936/moderna-novavax-shares-are-sliding-wednesday-whats-going-on

Trending Today

Ethereum ($ETH) Crypto Forecast: Up 5.1% Today

Uniswap ($UNI) Crypto Forecast: Up 5.1% Today

Sonic (prev. FTM) ($S) Crypto Forecast: Up 5.1% Today

Sui ($SUI) Crypto Forecast: Up 5.7% Today

Pepe ($PEPE) Crypto Forecast: Up 7.4% Today

PVH Corp. ($PVH) Stock Forecast: Up 18.4% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Up 6.8% Today

Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 7.1% Today

Groupon Inc. ($GRPN) Stock Forecast: Down 5.1% Today

AMC Entertainment Holdings Inc. Class A ($AMC) Stock Forecast: Down 5.1% Today

Novavax Inc. Price History

23.00.2025 - NVAX Stock was down 5.1%

• Wall Street analysts hold an optimistic view on the stock, projecting an 81.6% upside potential. However, NVAX faced significant bearish activity today.
• The discrepancy between the upbeat price targets and the current market performance may stem from profit-taking by investors capitalizing on past gains.
• Concerns about the company meeting analysts' high expectations could be prompting investors to sell their shares.
• Market dynamics, including broader economic conditions and sector rotation, may also be influencing the movement of NVAX and other high-growth stocks.

28.02.2025 - NVAX Stock was down 5.1%

• Novavax (NVAX) experienced a bearish movement likely due to profit-taking after a recent uptrend.
• Negative news surrounding plans to reduce financial support for vaccine efforts may have added to the selling pressure on Novavax shares.
• Investors may be concerned about the potential impact on Novavax's vaccine development and revenue streams, leading to the stock's decline.
• The broader market sentiment, combined with specific news related to vaccine funding, likely contributed to Novavax's bearish movement today.

14.01.2025 - NVAX Stock was up 6.4%

• Novavax (NVAX) exhibited strong bullish movement today, outperforming the broader market.
• The stock concluded the trading day at $8.19, reflecting a +0.74% change compared to the previous session.
• Factors contributing to this bullish trend could include advancements in Novavax's vaccine research or general market optimism towards the healthcare sector.
• Investors are displaying faith in Novavax's capacity to combat infectious diseases, propelling the stock's upward trajectory.

24.01.2025 - NVAX Stock was down 6.1%

• NVAX saw a decline in its stock price despite the general positivity in the vaccine market.
• Investors may have been let down by the lack of significant updates on NVAX's pipeline during the fourth-quarter earnings call.
• The increased concern about a new coronavirus causing another pandemic did not result in any concrete advancements for NVAX, contributing to the stock's decline.
• Profit-taking following recent stock price increases may have also impacted NVAX's performance.

19.01.2025 - NVAX Stock was down 5.1%

• The bearish movement in NVAX's stock could be due to investors' concerns about the updates on its pipeline during the fourth-quarter earnings call.
• If the updates on the pipeline did not meet investors' expectations, it could have led to a sell-off of NVAX shares.
• The market might be reacting negatively to any delays or setbacks in the development of Novavax's vaccines, leading to a decline in the stock price.

05.01.2025 - NVAX Stock was up 5.0%

• Novavax (NVAX) had a bullish trajectory, surpassing the overall market performance.
• The upturn in stock value may be linked to favorable developments within the company, possibly connected to progress in vaccine research and clinical trials.
• Investors are exhibiting confidence in Novavax's ability to tackle global health issues, leading to increased investment and pushing up the stock price.
• The market's reaction indicates optimism about Novavax's future outlook and its efforts in combatting infectious diseases.

25.01.2025 - NVAX Stock was down 6.0%

• NVAX stock experienced a bearish movement despite the anticipation of a new coronavirus triggering another pandemic, which usually boosts vaccine stocks.
• Investors may have had high expectations for NVAX's fourth-quarter earnings call, focusing on updates on its pipeline, and any disappointments or lack of positive updates could have led to the bearish movement.
• The overall market sentiment towards biotech stocks this earnings season may have influenced NVAX's performance, as investors assess the industry's outlook based on the upcoming earnings reports of various biotech companies.

15.00.2025 - NVAX Stock was up 5.1%

• NVAX demonstrated strong bullish momentum today amidst recent stock volatility.
• A bearish market trend earlier in the week was impacted by adverse news in the vaccine industry, including Moderna's revenue guidance being below expectations and respiratory illness concerns.
• Despite challenges within the vaccine sector, NVAX surged today, potentially driven by positive advancements in its vaccine pipeline or a shift in market sentiment in its favor.
• Investors might be reconsidering NVAX's long-term prospects, leading to the bullish movement in spite of recent industry setbacks.

16.00.2025 - NVAX Stock was down 5.1%

• Novavax (NVAX) witnessed a significant drop of 9.8% in its stock price today.
• The decrease in Novavax's stock value is linked to the pessimistic outlook surrounding vaccine stocks, influenced by Moderna's lower 2025 revenue projections.
• Moreover, the fluctuating nature of vaccine stocks, triggered by recent occurrences like the first US bird flu fatality and a report from the CDC highlighting an increase in respiratory illnesses, likely played a role in today's downturn for Novavax.

01.03.2025 - NVAX Stock was down 6.0%

• NVAX stock dipped more than the broader market, closing at $7.26, marking a -1.76% move from the prior day.
• Biotech stocks, including Novavax, fell after a top FDA official resigned due to irreconcilable differences with the new HHS Secretary, causing uncertainty in the sector.
• Reports about the Trump administration planning to cease financial support for vaccine alliance Gavi and scale back efforts to combat malaria added to the negative sentiment surrounding biotech stocks like Novavax.
• The combination of internal FDA issues and external government funding concerns likely contributed to the bearish movement in NVAX stock today.

27.01.2025 - NVAX Stock was down 8.7%

• Despite reporting a narrower Q4 loss and sales surpassing expectations, Novavax saw a decline in its stock value.
• Investor concerns may have arisen due to the company's strategic shift towards enhancing value rather than solely focusing on commercializing the COVID-19 vaccine.
• The surge in vaccine stocks, including NVAX, following the news of a new coronavirus discovered by Chinese scientists might have prompted profit-taking actions by investors, leading to the stock's decline.
• The market's response could also be linked to uncertainties surrounding Novavax's upcoming earnings report, with investors eagerly anticipating insights into the company's financial outlook.

27.01.2025 - NVAX Stock was up 6.2%

• A recent financial update from Novavax highlighted a reduced loss in Q4 and a strategic shift towards maximizing value rather than focusing solely on commercializing the COVID-19 vaccine, instilling confidence among investors in the company's long-term plan.
• The release of a positive earnings report, revealing sales of $88.31 million and an EPS loss in line with expectations, has contributed to the upward trend of NVAX stock.
• Investor interest in Novavax has been piqued by the company's projected adjusted revenue of $300-$350 million for 2025, indicating optimism about its future performance.
• The broader uptrend in vaccine stocks, including NVAX, following the identification of a new coronavirus strain in China, has further bolstered the positive outlook on the company's prospects and its potential in addressing future pandemics.